A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

被引：0
|
作者：
Salles, Gilles [1 ]
Shah, Harsh [2 ]
Leonard, John P. [3 ]
Szanto, Attila [4 ]
Chen, Jade [4 ]
Bannerji, Rajat [4 ]
Morschhauser, Franck [5 ]
Nastoupil, Loretta J. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Weill Cornell Med, New York, NY USA
[4] Epizyme, Cambridge, MA USA
[5] Univ Lille, CHU Lille, ULR 7365, GRITA,Grp Rech Formes Injectables & Technol Assoc, Lille, France
[6] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
IBCL; follicular lymphoma; non-Hodgkin lymphoma; enhancer of zeste homolog 2 protein; epigenetics; tazemetostat; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-485
引用
收藏
页码：S454 / S455
页数：2
相关论文
共 50 条
  • [41] A multicenter, randomized, double-blind, placebo controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE).
    Fowler, Nathan Hale
    Flinn, Ian
    Rule, Simon
    Chen, Robert W.
    Kwei, Long
    Beaupre, Darrin M.
    Chu, Alvina D.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
    Fowler, Nathan
    Kahl, Brad S.
    Lee, Peter
    Matous, Jeffrey V.
    Cashen, Amanda F.
    Jacobs, Samuel A.
    Letzer, Jeffrey
    Amin, Bipinkumar
    Williams, Michael E.
    Smith, Sonali
    Saleh, Alfred
    Rosen, Peter
    Shi, Hongliang
    Parasuraman, Sudha
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3389 - 3395
  • [43] Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
    Trneny, Marek
    Leonard, John P.
    Zhang, Huilai
    Nowakowski, Grzegorz
    Izutsu, Koji
    Fowler, Nathan H.
    Thieblemont, Catherine
    Zinzani, Pier Luigi
    Kalambakas, Stacey
    Czuczman, Myron
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2019, 134
  • [44] HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
    Stevens, Wendy B. C.
    Bakunina, Katerina
    Cuijpers, Marloes
    Chamuleau, Martine
    Beeker, Aart
    Fijnheer, Rob
    Hebart, Holger
    Visser, Hein P. J.
    Doorduijn, Jeanette K.
    Linton, Kim
    Dreyling, Martin
    de Jong, Daphne
    Kersten, Marie Jose
    HEMASPHERE, 2020, 4 (01):
  • [45] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up
    Salles, Gilles
    Park, Steven I.
    Phillips, Tycel J.
    Amengual, Jennifer E.
    Andorsky, David J.
    Campbell, Philip
    McKay, Pamela
    Leonard, John P.
    Chen, Yingxue
    Chen, Jade
    Bannerji, Rajat
    Kapopara, Apoorva
    Szanto, Attila
    Morschhauser, Franck
    BLOOD, 2023, 142
  • [46] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
    Vitolo, Umberto
    Merli, Michele
    Norasetthada, Lalita
    Wassenaar, Timothy Robert
    Martin, Eva Maria Donato
    Bobillo, Sabela
    Shen, Biyi
    Flink, Dina M.
    Zhu, Min
    Chandrasekharan, Soujanya
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Cordoba, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Hari, P.
    Lin, H. M.
    Zhu, Y.
    Berg, D.
    Richardson, P.
    Moreau, P.
    HAEMATOLOGICA, 2017, 102 : 297 - 298
  • [48] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
  • [49] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    Sakai, R.
    Ohmachi, K.
    Sano, F.
    Watanabe, R.
    Takahashi, H.
    Takasaki, H.
    Tanaka, M.
    Hattori, Y.
    Kimura, H.
    Takimoto, M.
    Tachibana, T.
    Tanaka, E.
    Ishii, Y.
    Ishiyama, Y.
    Hagihara, M.
    Miyazaki, K.
    Yamamoto, K.
    Tomita, N.
    Ando, K.
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2131 - 2138
  • [50] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
12345